受强制性开放获取政策约束的文章 - Min Yuen Teo了解详情
无法在其他位置公开访问的文章：8 篇
LBA-17 Multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma
JA Coleman, NC Wong, DD Sjoberg, N Silva, BH Bochner, G Dalbagni, ...
Journal of Urology 201, e999, 2019
强制性开放获取政策： US National Institutes of Health
PD36-08 PERIOPERATIVE OUTCOMES OF RADICAL CYSTECTOMY FOLLOWING NEOADJUVANT GEMCITABINE, CISPLATIN AND ATEZOLIZUMAB
A Mouzannar, K Whiting, I Ostrovnaya, A Katims, T Durdin, Z Feuer, ...
Journal of Urology 209 (Supplement 4), e983, 2023
强制性开放获取政策： US National Institutes of Health
PD47-03 CHARACTERIZING THE LANDSCAPE OF ACTIONABLE GENOMIC ALTERATIONS TO IDENTIFY OPPORTUNITIES FOR TARGETED THERAPY TRIALS IN PATIENTS WITH LOCALIZED BLADDER CANCER
N Almassi, E Pietzak, N Schultz, A Walasek, H Al-Ahmadie, MY Teo, ...
Journal of Urology 201, e838, 2019
强制性开放获取政策： US National Institutes of Health
MP82-07 TRENDS IN PERIOPERATIVE MANAGEMENT AND OUTCOMES IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA FOLLOWING RADICAL NEPHROURETECTOMY AT MEMORIAL SLOAN KETTERING CANCER …
NC Wong, M Assel, A Tracey, RG Alvim, N Almassi, N Singla, G Chesnut, ...
Journal of Urology 203, e1248, 2020
强制性开放获取政策： US National Institutes of Health
PD47-02 “ACTIONABLE” GENOMIC ALTERATIONS IN CHEMOTHERAPY RESISTANT MUSCLE-INVASIVE BLADDER CANCER
L Telis, T Clinton, N Almassi, MY Teo, S Funt, T Donahue, N Schultz, ...
Journal of Urology 203, e925-e926, 2020
强制性开放获取政策： US National Institutes of Health
PD42-06 DEFINING THE GENETIC EVOLUTION OF EPIGENETIC ALTERATIONS IN BLADDER CANCER
T Clinton, H Wise, N Almassi, S Chavan, W Hu, S Dason, E Pietzak, ...
Journal of Urology 203, e829, 2020
强制性开放获取政策： US National Institutes of Health
MP63-13 NEXT-GENERATION SEQUENCING REVEALS GENOMIC DIFFERENCES BETWEEN MALE AND FEMALE PATIENTS WITH UROTHELIAL CARCINOMA
A Walasek, B Wankel, N Almassi, MY Teo, S Funt, N Schultz, G Dalbagni, ...
Journal of Urology 201, e901-e902, 2019
强制性开放获取政策： US National Institutes of Health
MP57-10 CHARACTERIZATION OF MOLECULAR DIFFERENCES BETWEEN SMOKERS AND NON-SMOKERS WITH UROTHELIAL CARCINOMA
A Walasek, B Wankel, N Almassi, MY Teo, S Funt, N Schultz, G Dalbagni, ...
Journal of Urology 201, e816, 2019
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：32 篇
Treatment of advanced prostate cancer
MY Teo, DE Rathkopf, P Kantoff
Annual review of medicine 70 (1), 479-499, 2019
强制性开放获取政策： US National Institutes of Health
Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers
MY Teo, K Seier, I Ostrovnaya, AM Regazzi, BE Kania, MM Moran, ...
Journal of Clinical Oncology 36 (17), 1685-1694, 2018
强制性开放获取政策： US National Institutes of Health
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ...
Cell 185 (3), 563-575. e11, 2022
强制性开放获取政策： US National Institutes of Health
DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma
MY Teo, RM Bambury, EC Zabor, E Jordan, H Al-Ahmadie, ME Boyd, ...
Clinical cancer research 23 (14), 3610-3618, 2017
强制性开放获取政策： US National Institutes of Health
Genomic differences between “primary” and “secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy
EJ Pietzak, EC Zabor, A Bagrodia, J Armenia, W Hu, A Zehir, S Funt, ...
European urology 75 (2), 231-239, 2019
强制性开放获取政策： US National Institutes of Health
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
D Liu, P Abbosh, D Keliher, B Reardon, D Miao, K Mouw, A Weiner-Taylor, ...
Nature communications 8 (1), 2193, 2017
强制性开放获取政策： US National Institutes of Health, Damon Runyon Cancer Research Foundation
Cancer susceptibility mutations in patients with urothelial malignancies
MI Carlo, V Ravichandran, P Srinavasan, C Bandlamudi, Y Kemel, ...
Journal of Clinical Oncology 38 (5), 406-414, 2020
强制性开放获取政策： US National Institutes of Health
PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: concordance among 3 commonly used and commercially available antibodies
H Reis, R Serrette, J Posada, V Lu, Y Chen, A Gopalan, SW Fine, ...
The American journal of surgical pathology 43 (7), 920-927, 2019
强制性开放获取政策： US National Institutes of Health
Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial
SA Funt, M Lattanzi, K Whiting, H Al-Ahmadie, C Quinlan, MY Teo, ...
Journal of Clinical Oncology 40 (12), 1312-1322, 2022
强制性开放获取政策： US National Institutes of Health
Multicenter phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma
JA Coleman, W Yip, NC Wong, DD Sjoberg, BH Bochner, G Dalbagni, ...
Journal of Clinical Oncology 41 (8), 1618-1625, 2023
强制性开放获取政策： US National Institutes of Health
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
P Grivas, Y Loriot, R Morales-Barrera, MY Teo, Y Zakharia, S Feyerabend, ...
BMC cancer 21 (1), 593, 2021
强制性开放获取政策： US National Institutes of Health
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy
Y Ged, JL Chaim, RG DiNatale, A Knezevic, RR Kotecha, MI Carlo, ...
Journal for immunotherapy of cancer 8 (1), 2020
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定